Cost-effectiveness of CDK4/6 inhibitors in HR+/HER2- metastatic breast cancer: a systematic review and meta-analysis.

Prajakta P MasurkarPrachi PrajapatiJoanne CanedoSwarnali GoswamiSally EarlKaustuv Bhattacharya

Published in: Current medical research and opinion (2024)

The combination of CDK4/6 inhibitors and letrozole/endocrine therapy for the treatment of postmenopausal patients with advanced HR+/HER2 - MBC was not cost-effective.

Keyphrases

metastatic breast cancer
cell cycle
polycystic ovary syndrome
skeletal muscle
postmenopausal women
breast cancer risk